Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • P33 EFFECTIVENESS AND SAFETY O...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
P33 EFFECTIVENESS AND SAFETY OF BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN REAL-LIFE SETTING: THE ALFA STUDY

P33 EFFECTIVENESS AND SAFETY OF BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN REAL-LIFE SETTING: THE ALFA STUDY

Bibliographic Details
Main Authors: M. Roussel, N. Texier, R. Germain, S. Sapra, P. Paka, N. Kerbouche, X. Colin, X. Leleu
Format: Article
Language:English
Published: Wiley 2023-05-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/01.HS9.0000936260.48784.ae
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://journals.lww.com/10.1097/01.HS9.0000936260.48784.ae

Similar Items

  • The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma
    by: Melody R. Becnel, et al.
    Published: (2020-12-01)
  • The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development
    by: Pralay Mukhopadhyay, et al.
    Published: (2025-02-01)
  • Patient-reported experiences during and following treatment with belantamab mafodotin for relapsed/refractory multiple myeloma in the DREAMM-2 study
    by: Anna Cardellino, et al.
    Published: (2023-12-01)
  • P20: POLYCENTRIC “REAL LIFE” STUDY OF BELANTAMAB MAFODOTIN FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
    by: R Iula, et al.
    Published: (2022-04-01)
  • Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)
    by: Sagar Lonial, et al.
    Published: (2021-05-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs